Indeed, several chemoprevention trials have reported that the reduction in biomarkers of cancer risk (e.g., aflatoxin-DNA adducts) following SFN intervention was predominantly observed in subjects with the GSTM1-null genotype (58). The gene discussed is GSTM1; the disease is cancer.